Faced with stress and brain fog, columnist Juliet Taylor thought that staying on top of things would keep her husband's ALS ...

The first patient has been dosed in a Phase 2 clinical trial testing RAG-17 in people with ALS who carry mutations in the ...

Clene is scheduled to meet with the FDA in the coming months to discuss new data for CNM-Au8, its experimental oral therapy ...

The FDA granted fast track status to VectorY’s VTx-002, an antibody gene therapy targeting TDP-43 protein aggregates in ALS.

The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS ...

The ALS Association is urging members of Congress to take action to address issues with instability in leadership at the NIH.

Reflecting on past journal entries reminds columnist Kristin Neva that life as an ALS caregiver is always a mix of good and hard times.

With ALS, columnist Dagmar Munn says she must focus her mind and make deliberate choices when decision-making fatigue sets in.